Deferred Tax Assets, Net of Valuation Allowance of Lineage Cell Therapeutics, Inc. from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
Lineage Cell Therapeutics, Inc. quarterly Deferred Tax Assets, Net of Valuation Allowance in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • Lineage Cell Therapeutics, Inc. Deferred Tax Assets, Net of Valuation Allowance for the quarter ending 31 Dec 2025 was $20,105,000, a 183% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Change (%)

Lineage Cell Therapeutics, Inc. Quarterly Deferred Tax Assets, Net of Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $20,105,000 +$12,991,000 +183% 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q4 2024 $7,114,000 +$2,389,000 +51% 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q4 2023 $4,725,000 +$4,226,000 +847% 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q4 2022 $499,000 -$11,628,000 -96% 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q4 2021 $12,127,000 -$1,697,000 -12% 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q4 2020 $13,824,000 +$10,509,000 +317% 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q4 2019 $3,315,000 31 Dec 2019 10-K 11 Mar 2021 2020 FY
Q4 2014 $9,494,000 -$1,216,000 -15% 31 Dec 2014 10-K 11 Mar 2015 2014 FY
Q4 2013 $8,278,000 -$8,278,000 31 Dec 2013 10-K 11 Mar 2015 2014 FY
Q4 2012 $0 $0 31 Dec 2012 10-K 17 Mar 2014 2013 FY
Q4 2011 $0 31 Dec 2011 10-K 18 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.